{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:53:56Z","timestamp":1781880836196,"version":"3.54.5"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04201-8","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:20:52Z","timestamp":1769167252000},"page":"2481-2497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring correlations of CA19-9 with serum enzyme ratios: can layered biomarker strategies enhance prognostic accuracy in pancreatic cancer?"],"prefix":"10.1007","volume":"28","author":[{"given":"Akanksha","family":"Saini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Kumar","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor Kumar","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2535-2729","authenticated-orcid":false,"given":"Rina","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"4201_CR1","doi-asserted-by":"crossref","unstructured":"Bordoloi D, Sailo BL, Manteghi N, Padmavathi G, Kunnumakkara AB (2018) Introduction and basic concepts of cancer. Cancer Cell Chemoresistance And Chemosensitization 1\u201314","DOI":"10.1142\/9789813208575_0001"},{"key":"4201_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851\u201362.","journal-title":"JAMA"},{"key":"4201_CR3","unstructured":"Causes & Risk Factors - Pancreatic Cancer | Johns Hopkins Pathology. https:\/\/pathology.jhu.edu\/pancreas\/causes-risk-factors. Accessed 17 Sep 2025"},{"key":"4201_CR4","first-page":"245","volume":"70","author":"CL Rock","year":"2020","unstructured":"Rock CL, Thomson C, Gansler T, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin. 2020;70:245\u201371.","journal-title":"CA Cancer J Clin"},{"key":"4201_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.3007094","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, et al. Detection of 0. Sci Transl Med. 2014. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3007094.","journal-title":"Sci Transl Med"},{"key":"4201_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/jama.2013.284664","volume":"311","author":"NA Schultz","year":"2014","unstructured":"Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311:392\u2013404.","journal-title":"JAMA"},{"key":"4201_CR7","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1200\/JCO.2006.08.2644","volume":"24","author":"GY Locker","year":"2006","unstructured":"Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313\u201327.","journal-title":"J Clin Oncol"},{"key":"4201_CR8","unstructured":"Pancreatic Cancer - Gastrointestinal Disorders - Merck Manual Professional Edition. https:\/\/www.merckmanuals.com\/professional\/gastrointestinal-disorders\/tumors-of-the-gastrointestinal-tract\/pancreatic-cancer. Accessed 17 Sep 2025"},{"key":"4201_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-022-02640-9","volume":"22","author":"H Wu","year":"2022","unstructured":"Wu H, Ou S, Zhang H, Huang R, Yu S, Zhao M, et al. Advances in biomarkers and techniques for pancreatic cancer diagnosis. Cancer Cell Int. 2022;22:1\u201312.","journal-title":"Cancer Cell Int"},{"key":"4201_CR10","doi-asserted-by":"publisher","first-page":"12745","DOI":"10.18632\/oncotarget.23993","volume":"9","author":"D Teng","year":"2018","unstructured":"Teng D, Wu K, Sun Y, et al. Significant increased CA199 levels in acute pancreatitis patients predicts the presence of pancreatic cancer. Oncotarget. 2018;9:12745.","journal-title":"Oncotarget"},{"issue":"4","key":"4201_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/jcm14041129","volume":"14","author":"U Hayat","year":"2025","unstructured":"Hayat U, Croce PS, Saadeh A, Desai K, Appiah J, Khan S, et al. Current and emerging treatment options for pancreatic cancer: a comprehensive review. J Clinic Med. 2025;14(4):1129.","journal-title":"J Clinic Med"},{"key":"4201_CR12","unstructured":"Puckett Y, Garfield K (2024) Pancreatic Cancer. StatPearls"},{"key":"4201_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061523","volume":"14","author":"E Karamitopoulou","year":"2022","unstructured":"Karamitopoulou E. Molecular pathology of pancreatic cancer. Cancers (Basel). 2022;14:1523.","journal-title":"Cancers (Basel)"},{"key":"4201_CR14","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846\u201361.","journal-title":"World J Gastroenterol"},{"key":"4201_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"4201_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2468-1253(19)30416-9","volume":"5","author":"SP Pereira","year":"2020","unstructured":"Pereira SP, Oldfield L, Ney A, et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020;5:698\u2013710.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4201_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBCAN.2020.188409","author":"G Luo","year":"2021","unstructured":"Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochimica et Biophysica Acta (BBA) - Reviews Cancer. 2021. https:\/\/doi.org\/10.1016\/J.BBCAN.2020.188409.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"key":"4201_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092446","volume":"15","author":"GY Liou","year":"2023","unstructured":"Liou GY, Byrd CJ. Diagnostic bioliquid markers for pancreatic cancer: what we have vs. what we need. Cancers (Basel). 2023;15:2446.","journal-title":"Cancers (Basel)"},{"key":"4201_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1200\/JCO.23.02494","volume":"42","author":"M Milella","year":"2024","unstructured":"Milella M. Stage classification and prognosis assessment in localized pancreatic cancer: it takes two to tango. J Clin Oncol. 2024;42:1331\u20134.","journal-title":"J Clin Oncol"},{"key":"4201_CR20","doi-asserted-by":"publisher","DOI":"10.36255\/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer","author":"CAK Borrebaeck","year":"2022","unstructured":"Borrebaeck CAK, Mellby LD, King TC. Biomarkers for the early detection of pancreatic ductal adenocarcinoma. Gastrointest Cancer. 2022. https:\/\/doi.org\/10.36255\/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer.","journal-title":"Gastrointest Cancer"},{"key":"4201_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ECI.14341","author":"JE Gillson","year":"2025","unstructured":"Gillson JE, Byeon S, Chou A, et al. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Eur J Clin Invest. 2025. https:\/\/doi.org\/10.1111\/ECI.14341.","journal-title":"Eur J Clin Invest"},{"key":"4201_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejso.2006.10.004","volume":"33","author":"KS Goonetilleke","year":"2007","unstructured":"Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19\u20139) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266\u201370.","journal-title":"Eur J Surg Oncol"},{"key":"4201_CR23","doi-asserted-by":"crossref","unstructured":"E Poruk K, Z Gay D, Brown K, D Mulvihill J, M Boucher K, L Scaife C, A Firpo M, J Mulvihill S (2013) The clinical utility of CA 19\u20139 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 13(3):340\u2013351","DOI":"10.2174\/1566524011313030003"},{"key":"4201_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-019-6250-8","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Yang H, Lu J, Li D, Xu C, Risch HA. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. BMC Cancer. 2019. https:\/\/doi.org\/10.1186\/S12885-019-6250-8.","journal-title":"BMC Cancer"},{"key":"4201_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.21037\/hbsn-22-489","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, Gou A, Wu X. Liver metastasis of pancreatic cancer: the new choice at the crossroads. Hepatobiliary Surg Nutr. 2023;12:88.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"4201_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1245\/s10434-011-2020-9","volume":"19","author":"S Hata","year":"2012","unstructured":"Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, Shimada K, et al. Prognostic impact of postoperative serum CA 19\u20139 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19:636\u201341.","journal-title":"Ann Surg Oncol"},{"key":"4201_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s11605-012-1859-9","volume":"16","author":"T Sugiura","year":"2012","unstructured":"Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:977\u201385.","journal-title":"J Gastrointest Surg"},{"key":"4201_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.pan.2020.05.020","volume":"20","author":"H Takahashi","year":"2020","unstructured":"Takahashi H, Yamada D, Asukai K, et al. Clinical implications of the serum CA19-9 level in \u201cbiological borderline resectability\u201d and \u201cbiological downstaging\u201d in the setting of preoperative chemoradiation therapy for pancreatic cancer. Pancreatology. 2020;20:919\u201328.","journal-title":"Pancreatology"},{"key":"4201_CR29","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1245\/s10434-019-08156-3","volume":"27","author":"AI Al Abbas","year":"2020","unstructured":"Al Abbas AI, Zenati M, Reiser CJ, Hamad A, Jung JP, Zureikat AH, et al. Serum CA19-9 response to neoadjuvant therapy predicts tumor size reduction and survival in pancreatic adenocarcinoma. Ann Surg Oncol. 2020;27:2007\u201314.","journal-title":"Ann Surg Oncol"},{"key":"4201_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/SLA.0000000000005977","volume":"279","author":"AF Van Oosten","year":"2024","unstructured":"Van Oosten AF, Groot VP, Dorland G, Burkhart RA, Wolfgang CL, Van Santvoort HC, et al. Dynamics of serum CA19-9 in patients undergoing pancreatic cancer resection. Ann Surg. 2024;279:493\u2013500.","journal-title":"Ann Surg"},{"key":"4201_CR31","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s10620-011-1709-8","volume":"56","author":"S Singh","year":"2011","unstructured":"Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011;56:2491\u20136.","journal-title":"Dig Dis Sci"},{"key":"4201_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1507\/endocrj.EJ17-0380","volume":"65","author":"M Murakami","year":"2018","unstructured":"Murakami M, Nagai Y, Tenjin A, Tanaka Y. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study. Endocr J. 2018;65:639\u201343.","journal-title":"Endocr J"},{"key":"4201_CR33","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.pan.2016.09.013","volume":"16","author":"G Luo","year":"2016","unstructured":"Luo G, Guo M, Jin K, et al. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology. 2016;16:1057\u201362.","journal-title":"Pancreatology"},{"key":"4201_CR34","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.5501","volume":"13","author":"G Luo","year":"2016","unstructured":"Luo G, Jin K, Guo M, et al. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Oncol Lett. 2016;13:881.","journal-title":"Oncol Lett"},{"key":"4201_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/1354750X.2020.1725786","volume":"25","author":"L van Manen","year":"2020","unstructured":"van Manen L, Groen JV, Putter H, Vahrmeijer AL, Swijnenburg RJ, Bonsing BA, et al. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Biomarkers. 2020;25:186\u201393.","journal-title":"Biomarkers"},{"key":"4201_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1158\/1078-0432.CCR-14-0365","volume":"21","author":"DP O\u2019Brien","year":"2015","unstructured":"O\u2019Brien DP, Sandanayake NS, Jenkinson C, et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015;21:622\u201331.","journal-title":"Clin Cancer Res"},{"key":"4201_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ejso.2004.09.007","volume":"31","author":"XG Ni","year":"2005","unstructured":"Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"4201_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3892\/mco.2013.226","volume":"2","author":"Z Wang","year":"2014","unstructured":"Wang Z, TIAN YP. Clinical value of serum tumor markers CA19\u20139, CA125 and CA72\u20134 in the diagnosis of pancreatic carcinoma. Mol Clin Oncol. 2014;2(2):265\u20138.","journal-title":"Mol Clin Oncol"},{"key":"4201_CR39","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1158\/1078-0432.CCR-10-0248","volume":"17","author":"RE Brand","year":"2011","unstructured":"Brand RE, Nolen BM, Zeh HJ, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res. 2011;17:805\u201316.","journal-title":"Clin Cancer Res"},{"key":"4201_CR40","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1111\/cas.13712","volume":"109","author":"D Dong","year":"2018","unstructured":"Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, et al. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Sci. 2018;109:2841\u201351.","journal-title":"Cancer Sci"},{"key":"4201_CR41","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1002\/pmic.201200101","volume":"12","author":"HD Park","year":"2012","unstructured":"Park HD, Kang ES, Kim JW, et al. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics. 2012;12:3590\u20137.","journal-title":"Proteomics"},{"key":"4201_CR42","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00280-014-2450-8","volume":"73","author":"F Tas","year":"2014","unstructured":"Tas F, Karabulut S, Ciftci R, Sen F, Sakar B, Disci R, et al. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Cancer Chemother Pharmacol. 2014;73:1163\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4201_CR43","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ijc.26422","volume":"131","author":"J Liu","year":"2012","unstructured":"Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 2012;131:683\u201391.","journal-title":"Int J Cancer"},{"key":"4201_CR44","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1002\/cam4.5296","volume":"12","author":"R Zhao","year":"2023","unstructured":"Zhao R, Ren S, Li C, et al. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Cancer Med. 2023;12:5158\u201371.","journal-title":"Cancer Med"},{"issue":"1","key":"4201_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12957-019-1707-4","volume":"17","author":"F Jia","year":"2019","unstructured":"Jia F, Liu M, Li X, Zhang F, Yue S, Liu J. Relationship between S100A4 protein expression and pre-operative serum CA19 9 levels in pancreatic carcinoma and its prognostic significance. World J Surg Oncol. 2019;17(1):163.","journal-title":"World J Surg Oncol."},{"key":"4201_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3233\/CBM-190067","volume":"25","author":"X Xu","year":"2019","unstructured":"Xu X, Xiao Y, Hong B, Hao B, Qian Y. Combined detection of CA19-9 and B7\u2013H4 in the diagnosis and prognosis of pancreatic cancer. Cancer Biomark. 2019;25:251\u20137.","journal-title":"Cancer Biomark"},{"key":"4201_CR47","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1158\/1078-0432.CCR-23-0655","volume":"29","author":"M Dbouk","year":"2023","unstructured":"Dbouk M, Abe T, Koi C, et al. Diagnostic performance of a tumor marker gene test to personalize serum CA19-9 reference ranges. Clin Cancer Res. 2023;29:4178\u201385.","journal-title":"Clin Cancer Res"},{"key":"4201_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-14688-z","volume":"7","author":"ZAR Jawad","year":"2017","unstructured":"Jawad ZAR, Theodorou IG, Jiao LR, Xie F. Highly sensitive plasmonic detection of the pancreatic cancer biomarker CA 19\u20139. Sci Rep. 2017;7:1\u20137.","journal-title":"Sci Rep"},{"key":"4201_CR49","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1055-9965.EPI-18-0483","volume":"28","author":"J Song","year":"2019","unstructured":"Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, et al. Identification of serum biomarker panels for the early detection of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2019;28:174\u201382.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4201_CR50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrc3066","volume":"11","author":"H Schwarzenbach","year":"2011","unstructured":"Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426\u201337.","journal-title":"Nat Rev Cancer"},{"key":"4201_CR51","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.2147\/OTT.S100901","volume":"9","author":"S Salvi","year":"2016","unstructured":"Salvi S, Gurioli G, De Giorgi U, Conteduca V, Tedaldi G, Calistri D, et al. Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther. 2016;9:6549\u201359.","journal-title":"Onco Targets Ther"},{"key":"4201_CR52","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926\u201330.","journal-title":"Science"},{"issue":"4","key":"4201_CR53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JC Wan","year":"2017","unstructured":"Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"key":"4201_CR54","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","volume":"61","author":"E Heitzer","year":"2015","unstructured":"Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61:112\u201323.","journal-title":"Clin Chem"},{"key":"4201_CR55","first-page":"105","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19\u20139 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3:105\u201319.","journal-title":"J Gastrointest Oncol"},{"key":"4201_CR56","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36:1631\u201341.","journal-title":"J Clin Oncol"},{"key":"4201_CR57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.gie.2011.03.1235","volume":"74","author":"R Zubarik","year":"2011","unstructured":"Zubarik R, Gordon SR, Lidofsky SD, Anderson SR, Pipas JM, Badger G, et al. Screening for pancreatic cancer in a high-risk population with serum CA 19\u20139 and targeted EUS: a feasibility study. Gastrointest Endosc. 2011;74:87\u201395.","journal-title":"Gastrointest Endosc"},{"key":"4201_CR58","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00259-014-2688-8","volume":"41","author":"HX Xu","year":"2014","unstructured":"Xu HX, Chen T, Wang WQ, et al. Metabolic tumour burden assessed by 18F-FDG PET\/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging. 2014;41:1093\u2013102.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4201_CR59","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.hbpd.2019.03.010","volume":"18","author":"T Sakamoto","year":"2019","unstructured":"Sakamoto T, Saito H, Amisaki M, Tokuyasu N, Honjo S, Fujiwara Y. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19\u20139 level as a prognostic factor in patients with resected pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2019;18:278\u201384.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"4201_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/CNR2.1911","author":"S Chang","year":"2023","unstructured":"Chang S, Liu Y, Liang Y, Man Q, Li H, Guo Y, et al. Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreatic ductal adenocarcinoma. Cancer Rep (Hoboken). 2023. https:\/\/doi.org\/10.1002\/CNR2.1911.","journal-title":"Cancer Rep (Hoboken)"},{"key":"4201_CR61","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.21873\/anticanres.13264","volume":"39","author":"F Suzuki","year":"2019","unstructured":"Suzuki F, Fujiwara Y, Hamura R, Haruki K, Sakamoto T, Shiba H, et al. Combination of distance from superior mesenteric artery and serum CA19-9 as a novel prediction of local recurrence in patients with pancreatic cancer following resection. Anticancer Res. 2019;39:1469\u201378.","journal-title":"Anticancer Res"},{"key":"4201_CR62","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.pan.2018.08.003","volume":"18","author":"G Luo","year":"2018","unstructured":"Luo G, Fan Z, Cheng H, et al. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 2018;18:971\u20136.","journal-title":"Pancreatology"},{"key":"4201_CR63","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s11033-020-05245-5","volume":"47","author":"M Herreros-Villanueva","year":"2020","unstructured":"Herreros-Villanueva M, Ruiz-Rebollo L, Montes M, et al. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. Mol Biol Rep. 2020;47:1583\u20138.","journal-title":"Mol Biol Rep"},{"key":"4201_CR64","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12029-017-0007-x","volume":"49","author":"PLSU Junior","year":"2018","unstructured":"Junior PLSU, Callegaro-Filho D, Bugano DDG, Moura F, Maluf FC. Predictive value of serum carbohydrate antigen 19\u20139 (CA19-9) for early mortality in advanced pancreatic cancer. J Gastrointest Cancer. 2018;49:481\u20136.","journal-title":"J Gastrointest Cancer"},{"key":"4201_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-1782-x","volume":"17","author":"K Zhang","year":"2019","unstructured":"Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med. 2019;17:1\u20138.","journal-title":"J Transl Med"},{"key":"4201_CR66","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919900872","author":"JM Riedl","year":"2020","unstructured":"Riedl JM, Posch F, Prager G, et al. The AST\/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study. Ther Adv Med Oncol. 2020. https:\/\/doi.org\/10.1177\/1758835919900872.","journal-title":"Ther Adv Med Oncol"},{"key":"4201_CR67","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1002\/cam4.5556","volume":"12","author":"W Liao","year":"2023","unstructured":"Liao W, Yang Y, Yang H, Qu Y, Song H, Li Q. Circulating gamma-glutamyl transpeptidase and risk of pancreatic cancer: a prospective cohort study in the UK Biobank. Cancer Med. 2023;12:7877\u201387.","journal-title":"Cancer Med"},{"key":"#cr-split#-4201_CR68.1","unstructured":"Camara SN, Ramdany S, Traore S, et al (2015) Etiologic Link Between Chronic Pancreatitis and Pancreatic Cancer"},{"key":"#cr-split#-4201_CR68.2","doi-asserted-by":"crossref","unstructured":"A Unicentric Experience of Pancreatic Disease Institute of Wuhan Union Hospital of China. Journal of Surgery 2015, Volume 3, Page 59 3:59-65","DOI":"10.11648\/j.js.20150306.12"},{"key":"4201_CR69","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.pan.2021.05.300","volume":"21","author":"X Huang","year":"2021","unstructured":"Huang X, Lu Z, Zhang K, Wang G, Cai B, Wu P, et al. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9\/AST and CA19-9\/\u03b3-GGT for jaundiced PDAC patients). Pancreatology. 2021;21:1092\u2013101.","journal-title":"Pancreatology"},{"key":"4201_CR70","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13193-011-0042-1","volume":"2","author":"UK Ballehaninna","year":"2011","unstructured":"Ballehaninna UK, Chamberlain RS. Serum CA 19\u20139 as a biomarker for pancreatic cancer\u2014a comprehensive review. Indian J Surg Oncol. 2011;2:88.","journal-title":"Indian J Surg Oncol"},{"key":"4201_CR71","doi-asserted-by":"crossref","unstructured":"Lee MW, Park JM, Cho IR, Chung KH, Choi JH, Paik WH, Ryu JK, Kim BS, Han K Do, Lee SH (2025) Serum gamma-glutamyl transferase level is associated with the risk of pancreatic cystic neoplasms: A nationwide cohort study. medRxiv 2025.03.11.25323676","DOI":"10.1101\/2025.03.11.25323676"},{"key":"4201_CR72","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2217\/fon-2023-0137","volume":"19","author":"M Catalano","year":"2023","unstructured":"Catalano M, Roviello G, Aprile G, Ramello M, Conca R, Petrioli R, et al. Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer. Future Oncol. 2023;19:937\u201346.","journal-title":"Future Oncol"},{"key":"4201_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2024.1411096","author":"R del Campo-Pedrosa","year":"2024","unstructured":"del Campo-Pedrosa R, Mart\u00edn-Carnicero A, Gonz\u00e1lez-Marcos A, Mart\u00ednez A. New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/FONC.2024.1411096.","journal-title":"Front Oncol"},{"key":"4201_CR74","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/cam4.1957","volume":"8","author":"S Li","year":"2019","unstructured":"Li S, Xu H, Wu C, et al. Prognostic value of \u03b3-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Cancer Med. 2019;8:572\u201384.","journal-title":"Cancer Med"},{"key":"4201_CR75","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000236023","volume":"10","author":"B Diergaarde","year":"2010","unstructured":"Diergaarde B, Brand R, Lamb J, Cheong SY, Stello K, Barmada MM, et al. Pooling-based genome-wide association study implicates gamma-glutamyltransferase 1 (GGT1) gene in pancreatic carcinogenesis. Pancreatology. 2010;10:194\u2013200.","journal-title":"Pancreatology"},{"key":"4201_CR76","first-page":"1","volume":"15","author":"S Dong","year":"2017","unstructured":"Dong S, Wang L, Guo YB, Ying HF, Shen XH, Meng ZQ, et al. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. World J Surg Oncol. 2017;15:1\u20137.","journal-title":"World J Surg Oncol"},{"key":"4201_CR77","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3109\/1354750X.2012.701331","volume":"17","author":"M Porta","year":"2012","unstructured":"Porta M, Pumarega J, Guarner L, Malats N, Sol\u00e0 R, Real FX. Relationships of hepatic and pancreatic biomarkers with the cholestatic syndrome and tumor stage in pancreatic cancer. Biomarkers. 2012;17:557\u201365.","journal-title":"Biomarkers"},{"key":"4201_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-018-0891-y","volume":"18","author":"X Liu","year":"2018","unstructured":"Liu X, Fu Y, Chen Q, Wu J, Gao W, Jiang K, et al. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. BMC Gastroenterol. 2018;18:1\u20139.","journal-title":"BMC Gastroenterol"},{"key":"4201_CR79","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1016\/j.annonc.2020.04.280","volume":"31","author":"A Bengueddach","year":"2020","unstructured":"Bengueddach A, Kaid M, Kehili H, Tidjane A, Serradj NB, Tabeti B, et al. P-198 the AST\/ALT ratio predicts clinical outcome in pancreatic cancer patients treated with capecitabine and gemcitabine: a single institution experience in the west of Algeria. Ann Oncol. 2020;31:S154\u20135.","journal-title":"Ann Oncol"},{"key":"4201_CR80","doi-asserted-by":"publisher","first-page":"286","DOI":"10.5009\/gnl240322","volume":"19","author":"JH Heo","year":"2025","unstructured":"Heo JH, Kang JG, Han K, Lee KJ. Association between gamma-glutamyl transferase levels and pancreatobiliary cancer risk in patients with diabetes: evidence from the National Health Insurance Cooperation Health Checkup 2009 to 2012. Gut Liver. 2025;19:286\u201396.","journal-title":"Gut Liver"},{"issue":"1","key":"4201_CR81","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41598-025-85807-4","volume":"15","author":"X Zhao","year":"2025","unstructured":"Zhao X, Wang Y, Zhou L, Ye A, Zhu Q. Changes of CA19-9 levels and related influencing factors in patients with type 2 diabetes mellitus after antidiabetic therapy. Sci Rep. 2025;15(1):1264.","journal-title":"Sci Rep."},{"key":"4201_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1004590","author":"S Naudin","year":"2025","unstructured":"Naudin S, Wang M, Dimou N, et al. Alcohol intake and pancreatic cancer risk: an analysis from 30 prospective studies across Asia, Australia, Europe, and North America. PLoS Med. 2025. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1004590.","journal-title":"PLoS Med"},{"key":"4201_CR83","doi-asserted-by":"publisher","DOI":"10.21037\/APC-24-31","author":"H Delam","year":"2025","unstructured":"Delam H, Roosta M, Moghaddam S, Jahromi HK, Seidmohammadi K, Safari H. The role of alcohol as a risk factor in pancreatic cancer: a systematic review based on cohort and case-control studies. Ann Pancreat Cancer. 2025. https:\/\/doi.org\/10.21037\/APC-24-31.","journal-title":"Ann Pancreat Cancer"},{"key":"4201_CR84","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.2147\/CMAR.S313517","volume":"13","author":"SC Lyu","year":"2021","unstructured":"Lyu SC, Wang J, Huang M, Wang HX, Zhou L, He Q, et al. CA19-9 level to serum \u03b3-glutamyltransferase as a potential prognostic biomarker in patients with pancreatic head carcinoma. Cancer Manag Res. 2021;13:4887\u201398.","journal-title":"Cancer Manag Res"},{"key":"4201_CR85","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1053\/ejso.2002.1405","volume":"29","author":"FJF Engelken","year":"2003","unstructured":"Engelken FJF, Bettschart V, Rahman MQ, Parks RW, Garden OJ. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol. 2003;29:368\u201373.","journal-title":"Eur J Surg Oncol"},{"key":"4201_CR86","doi-asserted-by":"publisher","first-page":"128","DOI":"10.37047\/jos.2022-94940","volume":"9","author":"E Y\u00fcce","year":"2023","unstructured":"Y\u00fcce E, Fidan E, Y\u00fcce E, Fidan E. Gamma-Glutamyl Transferase\/Albumin Ratio and Alkaline Phosphatase\/Albumin Ratio as novel prognostic markers for metastatic pancreatic cancer. J Oncol Sci. 2023;9:128\u201333.","journal-title":"J Oncol Sci"},{"key":"4201_CR87","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/labmed\/lmad014","volume":"54","author":"M He","year":"2023","unstructured":"He M, Liu Y, Huang H, Wu J, Wu J, Wang R, et al. Serum aspartate aminotransferase is an adverse prognostic indicator for patients with resectable pancreatic ductal adenocarcinoma. Lab Med. 2023;54:608\u201312.","journal-title":"Lab Med"},{"key":"4201_CR88","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2020.16.1.60","author":"W Yang","year":"2020","unstructured":"Yang W, Kang D. Effects of gamma-glutamyl transferase on stroke occurrence mediated by atrial fibrillation. J Clin Neurol. 2020. https:\/\/doi.org\/10.3988\/jcn.2020.16.1.60.","journal-title":"J Clin Neurol"},{"key":"4201_CR89","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pan.2014.10.008","volume":"15","author":"AA Mohamed","year":"2015","unstructured":"Mohamed AA, Soliman H, Ismail M, Ziada D, Farid TM, Aref AM, et al. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer. Pancreatology. 2015;15:34\u20139.","journal-title":"Pancreatology"},{"key":"4201_CR90","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/818570","volume":"2015","author":"G Koenig","year":"2015","unstructured":"Koenig G, Seneff S. Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis Markers. 2015;2015:818570.","journal-title":"Dis Markers"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04201-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04201-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04201-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:04:39Z","timestamp":1781877879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04201-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":91,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4201"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04201-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that they possess no identified competing financial interests or personal ties that might have seemingly influenced the work presented in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}